A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

Yuan C. Ding, Lesley McGuffog, Sue Healey, Eitan Friedman, Yael Laitman, [No Value] Shani-Paluch-Shimon, Bella Kaufman, Annelie Liljegren, Annika Lindblom, Hakan Olsson, Ulf Kristoffersson, Marie Stenmark-Askmalm, Beatrice Melin, Susan M. Domchek, Katherine L. Nathanson, Timothy R. Rebbeck, Anna Jakubowska, Jan Lubinski, Katarzyna Jaworska, Katarzyna DurdaJacek Gronwald, Tomasz Huzarski, Cezary Cybulski, Tomasz Byrski, Ana Osorio, Teresa Ramony Cajal, Alexandra V. Stavropoulou, Javier Benitez, Ute Hamann, Matti Rookus, Cora M. Aalfs, Judith L. de Lange, Hanne E. J. Meijers-Heijboer, Jan C. Oosterwijk, Christi J. van Asperen, Encarna B. Gomez Garcia, Nicoline Hoogerbrugge, Agnes Jager, Rob B. van der Luijt, Douglas F. Easton, Susan Peock, Debra Frost, Steve D. Ellis, Radka Platte, Elena Fineberg, D. Gareth Evans, Fiona Lalloo, Louise Izatt, Ros Eeles, Julian Adlard, SWE-BRCA, HEBON, EMBRACE, GEMO Study Collaborators, kConFab Investigators, OCGN, Consortium Investigators Modifiers

OnderzoeksoutputAcademicpeer review

17 Citaten (Scopus)

Samenvatting

Background: We previously reported significant associations between genetic variants in insulin receptor substrate 1 (IRS1) and breast cancer risk in women carrying BRCA1 mutations. The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger cohort of BRCA1 and BRCA2 mutation carriers.

Methods: IRS1 rs1801123, rs1330645, and rs1801278 were genotyped in samples from 36 centers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Data were analyzed by a retrospective cohort approach modeling the associations with breast and ovarian cancer risks simultaneously. Analyses were stratified by BRCA1 and BRCA2 status and mutation class in BRCA1 carriers.

Results: Rs1801278 (Gly972Arg) was associated with ovarian cancer risk for both BRCA1 (HR, 1.43; 95% confidence interval (CI), 1.06-1.92; P = 0.019) and BRCA2 mutation carriers (HR, 2.21; 95% CI, 1.39-3.52, P = 0.0008). For BRCA1 mutation carriers, the breast cancer risk was higher in carriers with class II mutations than class I mutations (class II HR, 1.86; 95% CI, 1.28-2.70; class I HR, 0.86; 95%CI, 0.69-1.09; P-difference, 0.0006). Rs13306465 was associated with ovarian cancer risk in BRCA1 class II mutation carriers (HR, 2.42; P = 0.03).

Conclusion: The IRS1 Gly972Arg single-nucleotide polymorphism, which affects insulin-like growth factor and insulin signaling, modifies ovarian cancer risk in BRCA1 and BRCA2 mutation carriers and breast cancer risk in BRCA1 class II mutation carriers.

Impact: These findings may prove useful for risk prediction for breast and ovarian cancers in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev; 21(8); 1362-70. (C)2012 AACR.

Originele taal-2English
Pagina's (van-tot)1362-1370
Aantal pagina's9
TijdschriftCANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
Volume21
Nummer van het tijdschrift8
DOI's
StatusPublished - aug-2012

Citeer dit